Omnicell (NASDAQ:OMCL) Upgraded to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Omnicell (NASDAQ:OMCL) from a hold rating to a buy rating in a report released on Saturday morning.

Other equities research analysts have also issued reports about the company. Wells Fargo & Company raised their price objective on Omnicell from $52.00 to $55.00 and gave the stock an “overweight” rating in a research report on Thursday, April 23rd. Piper Sandler restated an “overweight” rating and set a $49.00 price objective (down from $63.00) on shares of Omnicell in a research report on Friday, February 6th. UBS Group set a $60.00 price objective on Omnicell and gave the stock a “buy” rating in a research report on Friday, March 13th. Bank of America upgraded Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price objective for the company in a research report on Wednesday, February 4th. Finally, Weiss Ratings lowered Omnicell from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, March 2nd. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $59.86.

Omnicell Trading Up 3.3%

Shares of NASDAQ OMCL opened at $42.80 on Friday. Omnicell has a one year low of $22.66 and a one year high of $55.00. The firm has a market capitalization of $1.95 billion, a PE ratio of 97.27, a PEG ratio of 1.56 and a beta of 0.96. The company has a current ratio of 1.50, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The business has a 50-day moving average price of $37.16 and a two-hundred day moving average price of $39.51.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The firm had revenue of $309.88 million during the quarter, compared to analyst estimates of $304.02 million. During the same period last year, the company posted $0.26 EPS. The business’s quarterly revenue was up 14.9% compared to the same quarter last year. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, analysts predict that Omnicell will post 1.34 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Corey J. Manley sold 7,405 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $34.69, for a total value of $256,879.45. Following the completion of the sale, the executive vice president directly owned 96,717 shares in the company, valued at approximately $3,355,112.73. The trade was a 7.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 2.92% of the company’s stock.

Institutional Investors Weigh In On Omnicell

Several institutional investors and hedge funds have recently added to or reduced their stakes in OMCL. AQR Capital Management LLC lifted its holdings in Omnicell by 42.1% in the 1st quarter. AQR Capital Management LLC now owns 17,936 shares of the company’s stock worth $627,000 after purchasing an additional 5,311 shares during the last quarter. Empowered Funds LLC lifted its holdings in Omnicell by 14.3% in the 1st quarter. Empowered Funds LLC now owns 9,953 shares of the company’s stock worth $348,000 after purchasing an additional 1,243 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Omnicell by 4.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company’s stock worth $4,337,000 after purchasing an additional 4,866 shares during the last quarter. Jane Street Group LLC lifted its holdings in Omnicell by 201.5% in the 1st quarter. Jane Street Group LLC now owns 163,664 shares of the company’s stock worth $5,722,000 after purchasing an additional 109,382 shares during the last quarter. Finally, Creative Planning lifted its holdings in Omnicell by 16.7% in the 2nd quarter. Creative Planning now owns 9,390 shares of the company’s stock worth $276,000 after purchasing an additional 1,347 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.